Amarin Corporation Plc · NASDAQ:AMRN
Amarin — Q1 2026 Earnings Presentation
13 slides from Amarin's earnings presentation, Apr 29, 2026
Slide 1: Evidence-Based Therapy to Reduce Life-Threatening Cardiovascular Events
EVIDENCE-BASED THERAPY TO REDUCE LIFE-THREATENING CARDIOVASCULAR EVENTS Company Overview NASDAQ: AMRN APRIL 2026
Slide 2: Forward Looking Statements & Disclaimer
Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (icosapent ethyl) (VAZKEPA® in Europe and in other territories), clinical and regulatory efforts and timelines, potential regulatory and prici
Slide 3: A Message from our President & CEO
A Message from our President & CEO “We are creating a new version of Amarin – focused, leaner, and both financially and operationally stronger. Our Q1 2026 results reflect the early, measurable progress generated by our refined global business model, which we implemented in mid-2025. We are expandin
Slide 4: Who We Are: An Established Leader in Cardiovascular Therapeutics
Who We Are: An Established Leader in Cardiovascular Therapeutics • First and only FDA-approved oral therapy to reduce cardiovascular (CV) risk when added to recommended statin therapy. • 2018 groundbreaking clinical study1 proved that VASCEPA (icosapent ethyl) lowers the chance of a life-threatening
Slide 5: Where We Stand: Leveraging a Global Footprint, Refined Strategy and Solid Financial Position
Where We Stand: Leveraging a Global Footprint, Refined Strategy and Solid Financial Position; Poised for Long-Term Growth • Transformed international commercial strategy; fully partnered and covering close to 100 countries; emphasis on Europe (Intellectual Property protection through 2039). • Restru
Slide 6: Our Financials: Executing a More Efficient Operating Model to Support Future Global Growth
Our Financials: Executing a More Efficient Operating Model to Support Future Global Growth Key Takeaways: Operating Results: ($ in M) Q1 26 Q1 25 Change Q1 2026 net revenue rose to $45.1 M Net Revenue 45.1 42.0 7% U.S. Product NR 35.6 35.7 (0)% Higher total revenue and lower total OPEX led to Europe
Slide 7: Our U.S. Business: Implemented and Successfully Executing Refined Commercial Strategy
Our U.S. Business: Implemented and Successfully Executing Refined Commercial Strategy to Maintain Profitable Branded Business • Proven efficacy in CVRR has built a large and durable U.S. market presence. • Executing on a refined commercial strategy focused on payer coverage post-loss of exclusivity,
Slide 8: Our International Business: Maximizing Ex-U.S. Access Through a Syndicate of Established Partners
Our International Business: Maximizing Ex-U.S. Access Through a Syndicate of Established Partners CANADA EUROPE Commercialization efforts New exclusive license & supply progressing agreement CHINA CVRR approval secured; Focus on Private Pay Market SOUTH KOREA AND ASEAN South Korea and Singapore regu
Slide 9: Our International Business: Recordati Partnership Key To Maximize VAZKEPA Opportunity in Europe
Our International Business: Recordati Partnership Key To Maximize VAZKEPA Opportunity in Europe • June 2025: exclusive, long-term license and supply agreement; 15- year initial term, auto renewal in 2039. • Recordati licensed to commercialize VAZKEPA in 59 countries, primarily Europe. COMPANY HIGHLI
Slide 10: Our International Business: Seven Partners Actively Building Market Opportunities Across Multiple Continents
Our International Business: Seven Partners Actively Building Market Opportunities Across Multiple Continents 7 Ex-U.S. partnerships focused on maximizing patient access to VASCEPA/ VAZKEPA – many in early commercialization stages, poised for future growth. Regulatory: o Monitoring regulatory reviews
Slide 11: Improving Market Dynamics: Regulatory Label Changes, Updated Guidelines & Amplified Disease Awareness
Improving Market Dynamics: Regulatory Label Changes, Updated Guidelines & Amplified Disease Awareness of Elevated Triglycerides/FCS Fibrate Label Change IPE in 2026 ACC/AHA/Multisociety Amplified Disease Awareness Dyslipidemia Guideline June 2025 - FDA updated the labelling Icosapent ethyl (IPE) is
Slide 12: 2026 Focus: Continued Execution & Driving Long-term Growth Opportunities
2026 Focus: Continued Execution & Driving Long-term Growth Opportunities A multi-pronged and multi-national approach: • Expand therapeutic reach across all partnered international markets. • Maintain IPE leadership in the U.S. • Realize the full operational improvements from global restructuring ini
Slide 13: Amarin Key Takeaways
Amarin Key Takeaways HEALTHY FINANCIALS UNTAPPED POTENTIAL PRODUCT POWER STRONG SCIENCE MEDICAL ENDORSEMENT Cash Flow ~640M PEOPLE LIVING WITH CVD, >260K 3 500+ EXPECT TO BE CASH FLOW MAKING IT THE LEADING CAUSE SUCCESSFUL PHASE 3 SCIENTIFIC PUBLICATIONS POSITIVE FOR FULL YEAR 2026 PRESCRIBERS OF DE